Literature DB >> 11241504

Apoptotic index by Annexin V flow cytometry: adjunct to morphologic and cytogenetic diagnosis of myelodysplastic syndromes.

S H Merchant1, N J Gonchoroff, R E Hutchison.   

Abstract

The myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by pancytopenia, dysplastic hematopoiesis, and a propensity to leukemic transformation. Increased apoptosis has been noted in MDS as a possible explanation for ineffective hematopoiesis, with lower levels in progression to and in de novo acute leukemia. Apoptosis can be measured by binding of Annexin V to exposed membrane phosphatidylserine. We postulated that the apoptotic index would aid in the differential diagnosis of MDS versus other hematopoietic diseases. We examined 33 bone marrow aspirates suspected of hematopoietic malignancy for apoptotic index by Annexin V analysis using a Becton Dickinson FACStar+ flow cytometer. The apoptotic index was expressed as the percentage of Annexin V-positive cells divided by total mononuclear cells in the gate. By standard morphologic analysis, 16 cases were diagnosed as MDS (9 refractory anemia [RA], 2 refractory anemia with ringed sideroblasts [RARS], 1 refractory anemia with excess of blasts [RAEB], 3 chronic myelomonocytic leukemia [CMML], and 1 unclassified), 11 as acute leukemia (AL), 6 as myeloproliferative disorders (MPD). Eight cases (uninvolved marrow of five patients with lymphoproliferative disorders [LPD], one patient with multiple myeloma, and two patients with anemia of chronic disease) served as nonneoplastic controls. A higher degree of apoptosis was observed in MDS (mean = 44.7%; range = 29.5--60%) compared with MPD (mean = 8.2%; range = 2.3--15.4%), AL (mean = 16.1%; range = 5.1--29.4%), and control marrow samples (mean = 11.6%; range = 1.5--21%). Additionally, the apoptotic index was significantly higher in MDS compared with MPD (P < 0.0001). In conclusion, a high apoptotic index occurs in MDS, supporting previous reports and suggesting that Annexin V analysis can be used as an adjunct in the diagnosis of MDS versus MPD. This would be particularly useful for the often-difficult distinction between early MDS and early MPD cases with equivocal morphology. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11241504     DOI: 10.1002/1097-0320(20010215)46:1<28::aid-cyto1034>3.0.co;2-h

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  7 in total

1.  Role of apoptotic markers in paediatric acute lymphoblastic leukaemia.

Authors:  Gauri Kapoor; Neha Singh
Journal:  Indian J Med Res       Date:  2018-03       Impact factor: 2.375

Review 2.  Growth differentiation factor 15 in erythroid health and disease.

Authors:  Toshihiko Tanno; Pierre Noel; Jeffery L Miller
Journal:  Curr Opin Hematol       Date:  2010-05       Impact factor: 3.284

3.  Neuroprotective effects of 3α-acetoxyeudesma-1,4(15),11(13)-trien-12,6α-olide against dopamine-induced apoptosis in the human neuroblastoma SH-SY5Y cell line.

Authors:  Uk Koo; Kung-Woo Nam; Ahrom Ham; Dahyun Lyu; Bora Kim; Sung-Jin Lee; Kyeong Ho Kim; Ki-Bong Oh; Woongchon Mar; Jongheon Shin
Journal:  Neurochem Res       Date:  2011-06-18       Impact factor: 3.996

4.  Iron Loading and Overloading due to Ineffective Erythropoiesis.

Authors:  Toshihiko Tanno; Jeffery L Miller
Journal:  Adv Hematol       Date:  2010-05-11

5.  Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4.

Authors:  Valeria Tosello; Rita Zamarchi; Anna Merlo; Margherita Gorza; Erich Piovan; Susanna Mandruzzato; Vincenzo Bronte; Xinhui Wang; Soldano Ferrone; Alberto Amadori; Paola Zanovello
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

6.  Pharmacodynamics of recombinant human erythropoietin in murine bone marrow.

Authors:  Peter J Bugelski; Thomas Nesspor; Amy Volk; Joanne O'Brien; Dorie Makropoulos; Kim Shamberger; Paul W Fisher; Ian James; Danielle Graden; Renold J Capocasale
Journal:  Pharm Res       Date:  2007-07-04       Impact factor: 4.200

7.  Revealing the Potential Application of EC-Synthetic Retinoid Analogues in Anticancer Therapy.

Authors:  Mohamed R Abdelaal; Sameh H Soror; Mohamed R Elnagar; Hesham Haffez
Journal:  Molecules       Date:  2021-01-19       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.